Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.67 |
| ▸ | ESR1 | P03372 | 10/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.56 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.54 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189382 | 0.91 | ABCG2 (0.66) | ABCG2CYP19A1ESR1ESR2CYP1A1 | |
| SCHEMBL3192349 | 0.88 | ESR1 (0.65) | ABCG2CYP19A1ESR1ESR2SOAT2 | |
| SCHEMBL3184162 | 0.88 | ESR1 (0.63) | ABCG2CYP19A1ESR1ESR2SOAT2 | |
| SCHEMBL3192994 | 0.85 | ABCG2 (0.55) | ABCG2CYP19A1ESR1ESR2CYP1A1 | |
| SCHEMBL30834874 | 0.77 | ESR1 (0.67) | ABCG2CYP19A1ESR1ESR2CACNA1G | |
| SCHEMBL28931303 | 0.76 | CYP19A1 (0.63) | ABCG2CYP19A1ESR1ESR2CYP1A1 | |
| SCHEMBL17387053 | 0.76 | ESR1 (1.00) | ABCG2CYP19A1ESR1ESR2CYP1A1 | |
| SCHEMBL30834916 | 0.75 | ESR1 (0.64) | ABCG2CYP19A1ESR1ESR2CACNA1G | |
| SCHEMBL5309150 | 0.75 | ESR1 (1.00) | ABCG2CYP19A1ESR1ESR2CYP1A1 | |
| 7,4'-Di-O-Methyl-8-Prenylnaringenin SCHEMBL29362493 | 0.75 | ABCG2 (0.85) | ABCG2CYP19A1ESR1ESR2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | claimed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | claimed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | claimed |
| CN-102018698-B | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-07-02 | — | — | CN | disclosed |
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | ESR2, ESR1, ESRRB | ABCG2 4748/4885CYP19A1 9/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.